Jan. 16, 2026 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were appr

Jan. 16, 2026 -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the commercial availability of the Freedom® PNS System for the treatment of chronic craniofacial pain. Freedom PNS is now the first and only PNS System in the United States available for this indication and supported by data from an FDA-approved Investigational Device Exemption (IDE) clinical study, allowing a greater patient population to benefit from PNS therapy. Craniofaci

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population Jan. 15, 2026 -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range

Jan. 15, 2026 -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive genetic selection tools, presented new data from its Phase 2b OLIVE trial at the American College of Neuropsychopharmacology (ACNP) Annual Meeting on January 14, 2026, in Atlantis, Bahamas. Dr. Hans Eriksson, Chief Medical Officer, presented clinical findings from the OLIVE Phase 2b trial, which evaluated BH-200 (neliva

Jan. 15, 2026 -- Juvenile Diabetes Cure Alliance (JDCA), a 501(c)(3) nonprofit solely focused on accelerating a cure for type 1 diabetes, announced the release of the 14th annual State of the Cure for Type 1 Diabetes (SOTC). This is the first publication to highlight the shift of cell supply research from the nonprofit to the commercial domain. Type 1 diabetes is a chronic autoimmune condition where insulin-producing cells are destroyed by the immune system, requiring lifelong dependence on ex

Jan. 15, 2026 -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion. Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently r

Jan. 14, 2026 -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This prestigious conference will be held April 17 to 22, 2026, in San Diego, California. Organized by the American Association for Cancer Research, this premier event gathers scientists, clinicians, and industry leaders from around the

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cash runway into Q3 2026 Jan. 15, 2026 -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the submission of an

Jan. 14, 2026 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for t

Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needs January 15, 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obst